Related references
Note: Only part of the references are listed.Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study
Mark C. Genovese et al.
JOURNAL OF RHEUMATOLOGY (2021)
Toll-like receptor signalling in B cells during systemic lupus erythematosus
Simon Fillatreau et al.
NATURE REVIEWS RHEUMATOLOGY (2021)
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease
Claire L. Langrish et al.
JOURNAL OF IMMUNOLOGY (2021)
Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition
Pavan Bhargava et al.
BRAIN (2021)
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study
D. F. Murrell et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages
Willianne Hoepel et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response
Kathryn Pellerin et al.
BRAIN (2021)
Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice
Jasper Rip et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
Variants in BANK1 are associated with lupus nephritis of European ancestry
Karin Bolin et al.
GENES AND IMMUNITY (2021)
T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia
Simo Xia et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Daniela Angst et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition
Albert Liclican et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2020)
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients
Steven P. Treon et al.
BLOOD (2020)
Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants
Ian M. Catlett et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19
Santiago Thibaud et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia
Isabella Quinti et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1 beta-mediated colitis
Liming Mao et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, PhaseIITrial
Stanley Cohen et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease
Sebastian Torke et al.
ACTA NEUROPATHOLOGICA (2020)
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover
Annarosa Soresina et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2020)
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Mark Roschewski et al.
SCIENCE IMMUNOLOGY (2020)
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
Krishnarup Ghoshdastidar et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Atypical course of COVID-19 in patient with Bruton agammaglobulinemia
Ivana Milosevic et al.
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES (2020)
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study
Peter H. Schafer et al.
RHEUMATOLOGY AND THERAPY (2020)
Inhibition of effector B cells by ibrutinib in systemic sclerosis
Jakob Einhaus et al.
ARTHRITIS RESEARCH & THERAPY (2020)
ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation
Christian Goess et al.
MODERN RHEUMATOLOGY (2019)
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)
Scott H. Watterson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models
Philipp Haselmayer et al.
JOURNAL OF IMMUNOLOGY (2019)
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Xavier Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies
Fu Gui et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Evidence for enhanced Bruton's tyrosine kinase activity in transitional and naive B cells of patients with granulomatosis with polyangiitis
Anouk von Borstel et al.
RHEUMATOLOGY (2019)
Functional rare and low frequency variants in BLK and BANK1 contribute to human lupus
Simon H. Jiang et al.
NATURE COMMUNICATIONS (2019)
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
Richard D. Caldwell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma
Hui Guo et al.
ONCOGENE (2019)
BTK signaling drives CD1dhiCD5+ regulatory B-cell differentiation to promote pancreatic carcinogenesis
Shipra Das et al.
ONCOGENE (2019)
Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease
Jasper Rip et al.
FRONTIERS IN IMMUNOLOGY (2019)
Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
Yuko Ariza et al.
BONE REPORTS (2019)
Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury
Jon M. Florence et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2018)
The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity
Jasper Rip et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2018)
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
Chengyuan Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development
James J. y Crawford et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Targeting B Cells and Plasma Cells in Autoimmune Diseases
Katharina Hofmann et al.
FRONTIERS IN IMMUNOLOGY (2018)
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
Matthew D. Blunt et al.
CLINICAL CANCER RESEARCH (2017)
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling
Andrew T. Bender et al.
MOLECULAR PHARMACOLOGY (2017)
Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?
Michaela Seeling et al.
NATURE REVIEWS RHEUMATOLOGY (2017)
Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care
Kathleen M. Gillooly et al.
PLOS ONE (2017)
Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment
Ailin Guo et al.
ONCOTARGET (2017)
Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease
Odilia B. J. Corneth et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity
Alexander N. R. Weber et al.
FRONTIERS IN IMMUNOLOGY (2017)
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers
Patrick F. Smith et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus
Yu-Yon Kim et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Ibrutinib: A Review in Chronic Lymphocytic Leukaemia
Emma D. Deeks
DRUGS (2017)
Targeting BTK through microRNA in chronic lymphocytic leukemia
A. Bottoni et al.
BLOOD (2016)
Btk inhibition treats TLR7/IFN driven murine lupus
Andrew T. Bender et al.
CLINICAL IMMUNOLOGY (2016)
The Neutrophil Btk Signalosome Regulates Integrin Activation during Sterile Inflammation
Stephanie Volmering et al.
IMMUNITY (2016)
Human effector B lymphocytes express ARID3a and secrete interferon alpha
Julie M. Ward et al.
JOURNAL OF AUTOIMMUNITY (2016)
Enhanced Expression of Bruton's Tyrosine Kinase in B Cells Drives Systemic Autoimmunity by Disrupting T Cell Homeostasis
Odilia B. J. Corneth et al.
JOURNAL OF IMMUNOLOGY (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
The adaptor protein CIN85 assembles intracellular signaling clusters for B cell activation
Julius Kuehn et al.
SCIENCE SIGNALING (2016)
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
Stefania Fiorcari et al.
ONCOTARGET (2016)
The adaptor protein CIN85 assembles intracellular signaling clusters for B cell activation
Julius Kuehn et al.
SCIENCE SIGNALING (2016)
A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells
Gayathri Natarajan et al.
ONCOIMMUNOLOGY (2016)
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis
Jin Kyun Park et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation
Sheau-Pey Wang et al.
RHEUMATOLOGY (2015)
Lubricin Restoration in a Mouse Model of Congenital Deficiency
Adele Hill et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Is It Time to Leave the Family? Comment on the Editorial by Gladman
Raffaele Scarpa
ARTHRITIS & RHEUMATOLOGY (2015)
Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants
Linda M. Hartkamp et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Antibody Reactivity of B Cells in Lupus Patients with Increased Disease Activity and ARID3a Expression
Julie M. Ward et al.
ANTIBODIES (2015)
Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex-induced acute lung injury
Agnieszka Krupa et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2014)
Genome-wide association studies in Sjogren's syndrome: What do the genes tell us about disease pathogenesis?
Peter D. Burbelo et al.
AUTOIMMUNITY REVIEWS (2014)
Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation
Vassilios Lougaris et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The immunoglobulin tail tyrosine motif upgrades memory-type BCRs by incorporating a Grb2-Btk signalling module
Niklas Engels et al.
NATURE COMMUNICATIONS (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci
Jose-Ezequiel Martin et al.
HUMAN MOLECULAR GENETICS (2013)
The BAFF Receptor Transduces Survival Signals by Co-opting the B Cell Receptor Signaling Pathway
Edina Schweighoffer et al.
IMMUNITY (2013)
Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: A potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints
Jonathan Hsu et al.
IMMUNOLOGY LETTERS (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bruton's Tyrosine Kinase Mediates the Synergistic Signalling between TLR9 and the B Cell Receptor by Regulating Calcium and Calmodulin
Elaine F. Kenny et al.
PLOS ONE (2013)
Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF
Eman Y. Abu-Rish et al.
RHEUMATOLOGY (2013)
Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans
Erica K. Evans et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice
Laurens P. Kil et al.
BLOOD (2012)
Meta-analysis reveals an association of PTPN22 C1858T with autoimmune diseases, which depends on the localization of the affected tissue
J. Zheng et al.
GENES AND IMMUNITY (2012)
Tyrosine Kinase Btk Is Required for NK Cell Activation
Yan Bao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents
Daigen Xu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORγt and LTi cells
Matthias Lochner et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
The transcription factor Bright plays a role in marginal zone B lymphocyte development and autoantibody production
Athenia L. Oldham et al.
MOLECULAR IMMUNOLOGY (2011)
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Julie A. Di Paolo et al.
NATURE CHEMICAL BIOLOGY (2011)
BAFF and selection of autoreactive B cells
Zheng Liu et al.
TRENDS IN IMMUNOLOGY (2011)
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
Betty Y. Chang et al.
ARTHRITIS RESEARCH & THERAPY (2011)
E-selectin engages PSGL-1 and CD44 through a common signaling pathway to induce integrin αLβ2-mediated slow leukocyte rolling
Tadayuki Yago et al.
BLOOD (2010)
Genes on the X chromosome affect development of collagen-induced arthritis in mice
L. JANSSON et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Genetics of SLE: evidence from mouse models
Laurence Morel
NATURE REVIEWS RHEUMATOLOGY (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
BAFF: a local and systemic target in autoimmune diseases
I. Moisini et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Genetic associations of LYN with systemic lupus erythematosus
R. Lu et al.
GENES AND IMMUNITY (2009)
B Cell Receptor-Mediated Sustained c-Rel Activation Facilitates Late Transitional B Cell Survival through Control of B Cell Activating Factor Receptor and NF-κB2
Iris Castro et al.
JOURNAL OF IMMUNOLOGY (2009)
Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-κB
Liang Yu et al.
BLOOD (2008)
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals
Masahiro Shinohara et al.
CELL (2008)
Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling
Jason E. Stadanlick et al.
NATURE IMMUNOLOGY (2008)
Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase
Sarah L. Doyle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Bruton's tyrosine kinase mediates NF-κB activation and B cell survival by B cell-activating factor receptor of the TNF-R family
Nicholas P. Shinners et al.
JOURNAL OF IMMUNOLOGY (2007)
Anti-nuclear antibody production and autoimmunity in transgenic mice that overexpress the transcription factor bright
Malini Shankar et al.
JOURNAL OF IMMUNOLOGY (2007)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
Bruton's tyrosine kinase and phospholipase C gamma 2 mediate chemokine-controlled B cell migration and homing
David J. J. de Gorter et al.
IMMUNITY (2007)
Bruton's tyrosine kinase is required for TLR-induced IL-10 production
Nathan W. Schmidt et al.
JOURNAL OF IMMUNOLOGY (2006)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3
Y Kawakami et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway
A Craxton et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Bruton's tyrosine kinase regulates immunoglobulin promoter activation in association with the transcription factor bright
J Rajaiya et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors
U Schmidt et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Expression and function of Tec, Itk, and Btk in lymphocytes: Evidence for a unique role for Tec
MG Tomlinson et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology
Y Sasaki et al.
JOURNAL OF IMMUNOLOGY (2004)
Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches
M Thien et al.
IMMUNITY (2004)
The B cell antigen receptor controls integrin activity through Btk and PLCγ2
M Spaargaren et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling deficient mice
ZSM Rahman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Predominant autoantibody production by early human B cell precursors
H Wardemann et al.
SCIENCE (2003)
Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor κB activation by toll-like receptor 4
CA Jefferies et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Cutting edge: B cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors
SH Smith et al.
JOURNAL OF IMMUNOLOGY (2003)
Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity
S Middendorp et al.
JOURNAL OF IMMUNOLOGY (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
BLNK:: molecular scaffolding through 'cis'-mediated organization of signaling proteins
CW Chiu et al.
EMBO JOURNAL (2002)
T cell activation in rheumatoid synovium is B cell dependent
S Takemura et al.
JOURNAL OF IMMUNOLOGY (2001)
Bruton's tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement
JB Petro et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Bruton's tyrosine kinase links the B cell receptor to nuclear factor κB activation
UD Bajpai et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
